# Opus Genetics Inc. (OCUP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $4.20 (+5.26%)

> Opus Genetics Inc. is a biotechnology company focusing on developing innovative gene therapies for inherited retinal diseases. Their primary mission is to address unmet medical needs for patients suffering from these rare genetic conditions that often lead to severe visual impairment or blindness. Opus Genetics leverages advanced gene therapy techniques to design and deliver solutions that target the root causes of such vision disorders. By concentrating on the sensory system, particularly the eyes, they aim to restore vision or significantly stall disease progression. The company operates at the intersections of genetic research, clinical development, and ophthalmology, influencing the broader healthcare and medical research sectors. As part of a niche but crucial industry within biotechnology, Opus Genetics plays a significant role in pioneering treatments that could potentially transform the lives of those affected by genetic ocular diseases. Their work underscores the vital importance of breakthrough biomedical research and innovation in improving quality of life for patients with chronic and debilitating conditions.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/OCUP)